Intellia Therapeutics(NTLA) - 2025 Q4 - Annual Results

Exhibit 99.1 Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates CAMBRIDGE, Mass., Feb. 26, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the fourth quarter and year ended December 31, 2025. "2025 was a time of accomplishment and resiliency for Intellia as we pres ...